The leading pharmaceutical company ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) plans to expand its business reach and market share. As per the reports, the company has decided to license the anti-clotting drug to a Bayer AG unit. The initial payment received by ISIS Pharmaceuticals for this drug is as much as $100 million.
What’s Next:
ISIS Pharmaceuticals’ new anti-clotting drug is an experimental drug and has the potential to perform better in the future. As per the reports, as soon as the formalities of this deal get over, the Bayer HealthCare will start focusing on developing and commercializing this drug in the future.
Bayer has bigger plans for this drug called ISIS-FXI. The company looks forward to evaluating it for all those patients who cannot use anticoagulants or the patients that have a huge risk of bleeding. Bayer has been trying hard to focus on thrombosis treatments over these years, and the current deal seems to take it closer to its focal point. As per the reports, it states that the anti-clotting drug named ISIS-FXI fulfills its expectations concerning the pipeline of thrombosis treatments. This is the primary reason Bayer decided to grab this opportunity as soon as it popped up.
Thrombosis is a complex procedure that involves the complete information about blood-clotting that sometimes results in strokes and heart attacks. Reports claim that Isis Pharmaceuticals is entitled to receive $55 million payment after the execution of phase 2 study in those patients who are suffering from compromised kidney function. As per the terms of the deal, it is also eligible for various royalties and milestone payments from time to time.
No one from the management of ISIS came forward to speak about this deal, which is expected to create value for all the shareholders in the coming months. Bayer is delighted to crack this offer and hopes that it will live up the expectations of all the stakeholders.
